CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease

British Journal of Clinical Pharmacology

Volumn 80, Issue 6, 2015, Pages 1421-1428

  Suzuki, Yosuke ^a   Fujioka, Takashi ^a   Sato, Fuminori ^b   Matsumoto, Kunihiro ^c   Muraya, Nanako ^a   Tanaka, Ryota ^a   Sato, Yuhki ^a   Ohno, Keiko ^c   Mimata, Hiromitsu ^b   Kishino, Satoshi ^c   Itoh, Hiroki ^a  

^a OITA UNIVERSITY HOSPITAL   (Japan)

^b OITA UNIVERSITY   (Japan)

^c MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

4 hydroxycholesterol; CYP3A activity; CYP3A5 polymorphism; kidney transplantation

Indexed keywords

4BETA HYDROXYCHOLESTEROL; ALANINE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL DERIVATIVE; CREATININE; CYTOCHROME P450 3A; CYTOCHROME P450 3A5; NITROGEN; UNCLASSIFIED DRUG; UREA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; ENZYME ACTIVITY; ENZYME POLYMORPHISM; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER FUNCTION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UREA NITROGEN BLOOD LEVEL; AGED; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; KIDNEY FAILURE, CHRONIC; LIVING DONOR; METABOLISM; MIDDLE AGED;

ADULT; AGED; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 84957564720     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12733     Document Type: Article

References (34)

1. Uchida N, Kurata N, Shimada K, Nishimura Y, Yasuda K, Hashimoto M, Uchida E, Yasuhara H,. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 1995; 68: 431-9.
2. Leblond FA, Giroux L, Villeneuve JP, Pichette V,. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 1317-20.
3. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V,. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12: 326-32.
4. Rege B, Krieg R, Gao N, Sarkar MA,. Down-regulation of hepatic CYP3A in chronic renal insufficiency. Pharm Res 2003; 20: 1600-6.
5. Naud J, Michaud J, Beauchemin S, Hébert MJ, Roger M, Lefrancois S, Leblond FA, Pichette V,. Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos 2011; 39: 1363-9.
6. Kusaba J, Kajikawa N, Kawasaki H, Kurosaki Y, Aiba T,. Comparative study on altered hepatic metabolism of CYP3A substrates in rats with glycerol-induced acute renal failure. Biopharm Drug Dispos 2012; 33: 22-9.
7. Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL,. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. Am J Kidney Dis 2015; 65: 574-82.
8. Guévin C, Michaud J, Naud J, Leblond FA, Pichette V,. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002; 137: 1039-46.
9. Hanada K, Ogawa R, Son K, Sasaki Y, Kikkawa A, Ichihara S, Ogata H,. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol 2006; 103: 179-86.
10. Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J, Pichette V,. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008; 108: 157-63.
11. Sun H, Huang Y, Frassetto L, Benet LZ,. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 2004; 32: 1239-46.
12. Zanger UM, Turpeinen M, Klein K, Schwab M,. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008; 392: 1093-108.
13. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E,. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383-91.
14. Streetman DS, Bertino JS Jr, Nafziger AN,. Phenotyping of drug-metabolizing enzymes in adults: a review of in vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216.
15. Karayalçin U, Takeda Y, Miyamori I, Morise T, Takeda R,. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: a preliminary study. Steroids 1991; 56: 598-600.
16. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK,. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998; 63: 617-22.
17. Galteau MM, Shamsa F,. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 713-33.
18. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, Kasuya Y,. Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 2003; 31: 1283-7.
19. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broomé U, Einarsson C, Diczfalusy U,. Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. J Biol Chem 2001; 276: 38685-9.
20. Bodin K, Andersson U, Rystedt E, Ellis E, Norlin M, Pikuleva I, Eggertsen G, Björkhem I, Diczfalusy U,. Metabolism of 4 beta -hydroxycholesterol in humans. J Biol Chem 2002; 277: 31534-40.
21. Suzuki Y, Itoh H, Sato F, Kawasaki K, Sato Y, Fujioka T, Sato Y, Ohno K, Mimata H, Kishino S,. Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. J Lipid Res 2013; 54: 2568-72.
22. Suzuki Y, Itoh H, Fujioka T, Sato F, Kawasaki K, Sato Y, Sato Y, Ohno K, Mimata H, Kishino S,. Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. Drug Metab Dispos 2014; 42: 105-10.
23. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S,. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 2010; 56: 32-8.
24. Huang SM, Temple R, Throckmorton DC, Lesko LJ,. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298-304.
25. Lalande L, Charpiat B, Leboucher G, Tod M,. Consequences of renal failure on non-renal clearance of drugs. Clin Pharmacokinet 2014; 53: 521-32.
26. Vinik HR, Reves JG, Greenblatt DJ, Abernethy DR, Smith LR,. The pharmacokinetics of midazolam in chronic renal failure patients. Anesthesiology 1983; 59: 390-4.
27. Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J,. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 2009; 20: 2269-76.
28. Gai Z, Chu L, Hiller C, Arsenijevic D, Penno CA, Montani JP, Odermatt A, Kullak-Ublick GA,. Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. Am J Physiol Renal Physiol 2014; 306: F130-7.
29. Diczfalusy U, Miura J, Roh HK, Mirghani RA, Sayi J, Larsson H, Bodin KG, Allqvist A, Jande M, Kim JW, Aklillu E, Gustafsson LL, Bertilsson L,. 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenet Genomics 2008; 18: 201-8.
30. Zhang Y, Zhang L, Abraham S, Apparaju S, Wu TC, Strong JM, Xiao S, Atkinson AJ Jr, Thummel KE, Leeder JS, Lee C, Burckart GJ, Lesko LJ, Huang SM,. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009; 85: 305-11.
31. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmöller J, Halpert JR, Zanger UM, Wojnowski L,. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773-9.
32. Michaud J, Naud J, Chouinard J, Désy F, Leblond FA, Desbiens K, Bonnardeaux A, Pichette V,. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006; 17: 3041-8.
33. Velenosi TJ, Feere DA, Sohi G, Hardy DB, Urquhart BL,. Decreased nuclear receptor activity and epigenetic modulation associates with down-regulation of hepatic drug-metabolizing enzymes in chronic kidney disease. FASEB J 2014; 28: 5388-97.
34. Honda A, Yamashita K, Hara T, Ikegami T, Miyazaki T, Shirai M, Xu G, Numazawa M, Matsuzaki Y,. Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. J Lipid Res 2009; 50: 350-7.